Our Bureau

MUMBAI: Lupin Ltd on Thursday said that it has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Cephalexin for Oral Suspension USP, 125 mg/5 ml and 250 mg/5 ml.

"We have identified cephalosporins as one of our focus areas for the US market.

The approval for Cephalexin will further boost our product basket. Given our leadership position in Cephalexin, we believe we will be able to drive value in the marketplace through forward-integration into the finished product,'' a press release said quoting Lupin's Chairman, Dr Desh Bandhu Gupta.

This is the company's sixth ANDA approved by the USFDA. Earlier it had received approvals for Ceftriaxone for injection, Cefotaxime for injection, Cefuroxime Axctil tablets and Cefixime tablets and oral suspension.